Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SOLV vs NMTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SOLV Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

SOLV Overall Winner 6-Pillar Tally: SOLV 6 – 0 NMTC Matrix Metrics: SOLV 8 – 2 NMTC

As of Nov 20, 2026, Solventum Corporation (SOLV) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SOLV carries a Unified Composite Score of 41.4/100 (SELL) at $84.50 (11.2x Forward P/E, 5.9% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin).

  • Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SOLV 41.4/100 SELL), SOLV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.9% vs. -63.4% operating margin) and revenue trajectory (-7.0% vs. +16.3% YoY).
  • Technical & Structure Timing Caution: SOLV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SOLV vs NMTC
SOLV NYSE Head-to-Head Winner
Solventum Corporation
Surgical & Medical Instruments & Apparatus
$84.50
-1.52% 1D
Market Cap $14.6B
TTM Revenue $8.16B
Forward P/E 11.2x
Beta / 30D Vol 0.51β · 36% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.5%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $86.52 · SMA50: $87.21
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (SOLV 6 – 0 NMTC)

Columns: Metric · SOLV · NMTC
1. Valuation Multiples SOLV
Forward P/E 11.2x N/M
Trailing P/E 96.4x N/M
PEG Ratio 1.22x N/M
EV / Revenue 2.4x 0.3x
2. Growth & Scale SOLV
Revenue Growth (YoY) -7.0% +16.3%
Earnings Growth (YoY) +3.9% +0.0%
TTM Revenue (USD) $8.16B $12M
Market Cap $14.6B $6.1M
3. Profitability & Quality SOLV
Gross Margin 53.8% 23.0%
Operating Margin 5.9% -63.4%
Net Profit Margin 1.9% -59.7%
Return on Equity (ROE) 3.2% -124.7%
4. Balance Sheet & Cash Flow SOLV
Cash Generation (TTM) $0 -$7.6M
Cash Flow Margin 0.0% -60.7%
Net Cash / Leverage $4.82B Net Debt (1.10x D/E) $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SOLV
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 54.9% (22nd %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SOLV
OpEx & R&D Intensity 47.9% of Rev ($3.91B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SOLV (8) vs NMTC (2)
Institutional Metric SOLV NMTC Criterion Row Edge
Market Capitalization
Scale
$14.6B $6.1M Larger Scale SOLV
Trailing P/E Ratio
Valuation
96.4x N/M Lower Multiple SOLV
Forward P/E Ratio
Valuation
11.2x N/M Lower Multiple SOLV
Revenue Growth (YoY)
Growth
-7.0% +16.3% Higher Growth NMTC
Operating Margin (TTM)
Profitability
5.9% -63.4% Higher Margin SOLV
Net Profit Margin
Profitability
1.9% -59.7% Higher Margin SOLV
Return on Equity (ROE)
Capital Efficiency
3.2% -124.7% Higher ROE SOLV
52-Week Range Position
Momentum
70% ($62–$94) 2% ($1–$5) Stronger Trend SOLV
Beta / 30D Volatility
Risk Regime
0.51β · 36% Vol 1.55β · 105% Vol Lower Realized Risk SOLV
Unified Institutional Score
Composite Signal
41.4 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite NMTC
Trailing 12M Revenue (USD)
Operating Scale
$8.16B $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.8% 23.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.22x PEG · 2.4x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$0 ($4.82B Net Debt (1.10x D/E)) -$7.6M ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SOLV +30.09 pp
SOLV: -3.37% · NMTC: -33.46%
3M Horizon SOLV +62.13 pp
SOLV: -7.4% · NMTC: -69.53%
6M Horizon SOLV +92.31 pp
SOLV: +9.98% · NMTC: -82.33%
1Y Horizon SOLV +5.81 pp
SOLV: +9.3% · NMTC: +3.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SOLV Revenue NMTC Revenue SOLV Op. Margin NMTC Op. Margin Margin Leader
FY2012 N/A $0M N/A -1491.1% NMTC
FY2013 N/A $0M N/A -2009.0% NMTC
FY2014 N/A $0M N/A -4646.1% NMTC
FY2021 N/A $0M N/A -5735.9% NMTC
FY2022 $8.13B $0M 20.8% -5860.2% SOLV
FY2023 $8.20B $0M 20.6% -612.3% SOLV
FY2024 $8.25B $0M 12.6% -344.3% SOLV
FY2025 $8.32B $10M 26.2% -46.5% SOLV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SOLV CONSOLIDATION
115d in phase · OBV DISTRIBUTION
Current IV 54.9%
IV Percentile 22nd %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SOLV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $87.06 · IV 34.0%

SOLV Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($8,706)

Compare $8,706 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 34.0% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $85 / $90 Bull Call Spread

Buy 1x $85C · Sell 1x $90C · 30d

Net Entry $184 Debit
T+5d @ +5% Move +$122 (+66%)
Max Risk / Buffer $184 Capped
5d Edge & Liquidity 1.1x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $80 / $75 Bull Put Spread

Sell 1x $80P · Buy 1x $75P · 58d

Net Entry $104 Credit
Max Credit / Yield +$104 (+26.3% RoM)
Max Risk / Buffer -9.3% Cushion ($396 Mgn)
5d Edge & Liquidity 80% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SOLV Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $14.6B market capitalization and 5.9% operating margin.
OpEx & R&D Reinvestment 47.9% of Rev ($3.91B)
90D Engineering Disclosures 0 Published
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SOLV vs NMTC Key Questions & Quantitative Answers

As of Nov 20, 2026, Solventum Corporation (SOLV) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SOLV carries a Unified Composite Score of 41.4/100 (SELL) at $84.50 (11.2x Forward P/E, 5.9% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SOLV 41.4/100 SELL), SOLV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.9% vs. -63.4% operating margin) and revenue trajectory (-7.0% vs. +16.3% YoY). Technical & Structure Timing Caution: SOLV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SOLV leads the Growth & Scale pillar: SOLV posts -7.0% YoY revenue growth and +3.9% YoY earnings growth on $8.16B TTM revenue (53.8% gross margin, 5.9% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), SOLV cumulative revenue shifted +2.3% while NMTC shifted N/A. In operating R&D and SG&A reinvestment, SOLV deploys 47.9% of Rev ($3.91B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.

SOLV screens cheaper on headline valuation multiples. SOLV trades at 11.2x Forward P/E, 96.4x Trailing P/E, 1.22x PEG, and 2.4x EV/Revenue (0.0% FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SOLV (3.2% ROE) versus NMTC (-124.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SOLV carries 54.9% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.51β · 36% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.